"The U.S. Food and Drug Administration today approved Dotarem (gadoterate meglumine) for use in magnetic resonance imaging (MRI) of the brain, spine and associated tissues of patients ages 2 years and older.
Dotarem is a gadolinium-based"...
Omniscan Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Omniscan (gadodiamide) injection is a magnetic resonance imaging (MRI) contrast agent that helps doctors see images of the brain, spine, chest, stomach, hip area, and other parts of the body. Common side effects include nausea, dizziness, headache, pain at injection site, or rash.
Omniscan is administered as a bolus dose IV injection under physician supervision. No specific drug interaction studies have been conducted. No adequate and well-controlled studies have been used with Omniscan and pregnancy; therefore, it should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. It is not known if Omniscan is excreted in human milk; discuss the use of Omniscan with your doctor if you are breastfeeding.
Our Omniscan (gadodiamide) injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Omniscan FDA Prescribing Information: Side Effects
The following adverse reactions are discussed in greater detail in other sections of the label:
- Nephrogenic systemic fibrosis [see WARNINGS AND PRECAUTIONS]
- Hypersensitivity reactions [see WARNINGS AND PRECAUTIONS]
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
Clinical Studies Experience (Adults)
In clinical studies 1160 patients were exposed to OMNISCAN. The most frequent adverse reactions were nausea, headache, and dizziness that occurred in 3% or less of the patients. The majority of these reactions were of mild to moderate intensity.
The following adverse reactions occurred in 1% or less of patients:
Application Site Disorders: Injection site reaction.
Autonomic Nervous System Disorders: Vasodilation.
Central and Peripheral Nervous System Disorders: Convulsions including grand mal, ataxia, abnormal coordination, paresthesia, tremor, aggravated multiple sclerosis (characterized by sensory and motor disturbances), aggravated migraine.
Liver and Biliary System Disorders: Abnormal hepatic function.
Special Senses, Other Disorders: Taste loss, taste perversion.
Urinary System Disorders: Acute reversible renal failure.
Vision Disorders: Abnormal vision.
Clinical Studies Experience (Pediatrics)
In the 97 pediatric patients in CNS studies with OMNISCAN [see Clinical Studies] and the 144 pediatric patients in published literature, the adverse reactions were similar to those reported in adults.
Because postmarketing reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
The following adverse reactions have been identified during the postmarketing use of OMNISCAN:
Nervous System Disorders: Inadvertent intrathecal use causes seizures, coma, paresthesia, paresis.
General Disorders: Nephrogenic Systemic Fibrosis (NSF) [see WARNINGS AND PRECAUTIONS].
Read the entire FDA prescribing information for Omniscan (Gadodiamide) »
Additional Omniscan Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.